Newswire Biotechnology News
Submitted by odvodca on Fri, 2009-05-08 10:35

Health Canada issued a NPN to Advitech for Dermylex

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TSX VENTURE EXCHANGE: AVI

Wed, 10 Mar 2010 17:15:00 EST

Bio-Processing Alliance Inc. Launches Comprehensive Consulting Business

TORONTO, March 10 /CNW/ - Bio-Processing Alliance Inc. announces its official launch of business. BPAI is a biologics drug development 'think tank' providing consultative direction and support in the management of complex biologics programs from concept, through to development and

Wed, 10 Mar 2010 16:32:00 EST

Spectral appoints two new board members

TORONTO, March 10 /CNW/ - Spectral Diagnostics Inc. (TSX:SDI), a company developing products for the treatment of sepsis, today announced the appointment of Mr. Kevin Giese, President, CEO and Director of BioMS Medical and Mr. Laine Woollard, QC, Senior Legal Counsel of TEC Edmonton, to the

Wed, 10 Mar 2010 13:00:00 EST

YM BioSciences closes US$17.5 million financing

MISSISSAUGA, ON, March 10 /CNW/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM), today announced that it has closed its previously announced "registered direct" offering of 14,583,000 million units at an issue price of US $1.20 for gross proceeds of approximately US $17.5 million. Each unit

Wed, 10 Mar 2010 13:00:00 EST

Oncolytics Biotech(R) Inc. Announces 2009 Year End Results

CALGARY, March 9 /CNW/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the year ended December 31, 2009. "In 2009, we executed on our business plan focused on preparing the

Tue, 9 Mar 2010 07:30:00 EST

Australia Substantially Increases Research Collaboration with China, According to Thomson Reuters Study

<< New Zealand researchers double collaboration with Spain and Norway

Tue, 9 Mar 2010 00:02:00 EST

YM BioSciences increases offering size to approximately US$17.5 million

MISSISSAUGA, ON, March 8 /CNW/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM), today announced that the previously announced offering of approximately US$15 million has been increased to approximately US$17.5 million.

Mon, 8 Mar 2010 08:49:00 EST

Cyplasin Initiates its Product Development Program

Attracts Top-Quality Management Team and Board Members CPBM: OTCBB XYI1:FRA

Fri, 5 Mar 2010 16:00:00 EST

Resverlogix Update

TSX Exchange Symbol: RVX CALGARY, March 5 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX), reports that in the March 5th, 2010 press release

Fri, 5 Mar 2010 12:54:00 EST

Resverlogix Market Update

TSX Exchange Symbol: RVX CALGARY, March 5 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX), at the request of the Investment Industry Regulatory

Fri, 5 Mar 2010 11:31:00 EST

ImaSight Announces Corporate Restructuring Pursuant to BIA Protection

OTTAWA, March 5 /CNW Telbec/ - ImaSight Corp announces today that a proposal to creditors has been accepted, resulting in the sale of the CRD-5 drug assets to Cerenis, effective February 19, 2010. On February 24, 2009, the Corporation sought BIA (Bankruptcy and

Fri, 5 Mar 2010 10:46:00 EST

YM BioSciences to raise approximately US$15 million

MISSISSAUGA, ON, March 5 /CNW/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM), today announced that it is raising approximately US$15 million in a "registered direct" offering of units at a price of US$1.20 per unit. Each unit consists of one common share and one half of one common share purchase

Fri, 5 Mar 2010 09:19:00 EST